Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis

We investigated Brucella melitensis methionyl-tRNA-synthetase (BmMetRS) with molecular, structural and phenotypic methods to learn if BmMetRS is a promising target for brucellosis drug development. Recombinant BmMetRS was expressed, purified from wild type Brucella melitensis biovar Abortus 2308 strain ATCC/CRP #DD-156 and screened by a thermal melt assay against a focused library of one hundred previously classified methionyl-tRNA-synthetase inhibitors of the blood stage form of Trypanosoma brucei. Three compounds showed appreciable shift of denaturation temperature and were selected for further studies on inhibition of the recombinant enzyme activity and cell viability against wild type B. melitensis strain 16M. BmMetRS protein complexed with these three inhibitors resolved into three-dimensional crystal structures and was analyzed. All three selected methionyl-tRNA-synthetase compounds inhibit recombinant BmMetRS enzymatic functions in an aminoacylation assay at varying concentrations. Furthermore, growth inhibition of B. melitensis strain 16M by the compounds was shown. Inhibitor-BmMetRS crystal structure models were used to illustrate the molecular basis of the enzyme inhibition. Our current data suggests that BmMetRS is a promising target for brucellosis drug development. However, further studies are needed to optimize lead compound potency, efficacy and safety as well as determine the pharmacokinetics, optimal dosage, and duration for effective treatment.

[1]  F. Buckner,et al.  Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Giardia intestinalis Trophozoites , 2015, Antimicrobial Agents and Chemotherapy.

[2]  Steven J Brown,et al.  Identification of Potent Inhibitors of the Trypanosoma brucei Methionyl-tRNA Synthetase via High-Throughput Orthogonal Screening , 2015, Journal of biomolecular screening.

[3]  F. Buckner,et al.  Structures of Trypanosoma brucei Methionyl-tRNA Synthetase with Urea-Based Inhibitors Provide Guidance for Drug Design against Sleeping Sickness , 2014, PLoS neglected tropical diseases.

[4]  F. Buckner,et al.  Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. , 2012, Journal of medicinal chemistry.

[5]  C. Verlinde,et al.  Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3. , 2011, Molecular and biochemical parasitology.

[6]  Wim G. J. Hol,et al.  Selective Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Trypanosoma brucei Infection in Mice , 2011, Antimicrobial Agents and Chemotherapy.

[7]  Vincent B. Chen,et al.  PHENIX: a comprehensive Python-based system for macromolecular structure solution , 2010, Acta crystallographica. Section D, Biological crystallography.

[8]  Gregory J. Crowther,et al.  Buffer Optimization of Thermal Melt Assays of Plasmodium Proteins for Detection of Small-Molecule Ligands , 2009, Journal of biomolecular screening.

[9]  T. Jarvis,et al.  Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. , 2009, The Journal of antimicrobial chemotherapy.

[10]  F. Dean,et al.  Inhibition of Methionyl-tRNA Synthetase by REP8839 and Effects of Resistance Mutations on Enzyme Activity , 2008, Antimicrobial Agents and Chemotherapy.

[11]  E. J. Young,et al.  Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations , 2007, PLoS medicine.

[12]  F. Mahoney,et al.  Brucellosis as a cause of acute febrile illness in Egypt. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[13]  Airlie J. McCoy,et al.  Solving structures of protein complexes by molecular replacement with Phaser , 2006, Acta crystallographica. Section D, Biological crystallography.

[14]  Sunghoon Kim,et al.  Pharmacophore-based virtual screening: the discovery of novel methionyl-tRNA synthetase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[15]  Wim G J Hol,et al.  Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. , 2006, Molecular and biochemical parasitology.

[16]  Georgios Pappas,et al.  The new global map of human brucellosis. , 2006, The Lancet. Infectious diseases.

[17]  F. Studier,et al.  Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.

[18]  P. Pasquali,et al.  Genetic Bases of the Rifampin Resistance Phenotype in Brucella spp , 2004, Journal of Clinical Microbiology.

[19]  P. Emsley,et al.  Coot: model-building tools for molecular graphics. , 2004, Acta crystallographica. Section D, Biological crystallography.

[20]  M. Vignali,et al.  A Facile Method for High-throughput Co-expression of Protein Pairs*S , 2004, Molecular & Cellular Proteomics.

[21]  L. Spremulli,et al.  Characterization of the human mitochondrial methionyl-tRNA synthetase. , 2004, Biochemistry.

[22]  I. Şencan,et al.  Ofloxacin plus Rifampicin versus Doxycycline plus Rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179] , 2004, BMC infectious diseases.

[23]  J. Madwed,et al.  Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796). , 2003, Journal of medicinal chemistry.

[24]  James R. Brown,et al.  Variable Sensitivity to Bacterial Methionyl-tRNA Synthetase Inhibitors Reveals Subpopulations of Streptococcus pneumoniae with Two Distinct Methionyl-tRNA Synthetase Genes , 2003, Antimicrobial Agents and Chemotherapy.

[25]  S. Choi,et al.  Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics , 2003, Applied Microbiology and Biotechnology.

[26]  A. K. Forrest,et al.  Optimisation of aryl substitution leading to potent methionyl tRNA synthetase inhibitors with excellent gram-positive antibacterial activity. , 2003, Bioorganic & medicinal chemistry letters.

[27]  L. Guilloteau,et al.  Functional Characterization of Brucella melitensis NorMI, an Efflux Pump Belonging to the Multidrug and Toxic Compound Extrusion Family , 2002, Antimicrobial Agents and Chemotherapy.

[28]  A. K. Forrest,et al.  Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. , 2002, Journal of medicinal chemistry.

[29]  J. Liautard,et al.  In Vitro Brucella suis Infection Prevents the Programmed Cell Death of Human Monocytic Cells , 2000, Infection and Immunity.

[30]  O. Nureki,et al.  Crystal structure of Escherichia coli methionyl-tRNA synthetase highlights species-specific features. , 1999, Journal of molecular biology.

[31]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[32]  M. J. Corbel,et al.  Brucellosis: an overview. , 1997, Emerging infectious diseases.

[33]  M. Meltzer,et al.  The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? , 1997, Emerging infectious diseases.

[34]  M. Plommet,et al.  Minimal requirements for growth of Brucella suis and other Brucella species. , 1991, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[35]  W. H. Hall,et al.  Modern chemotherapy for brucellosis in humans. , 1990, Reviews of infectious diseases.

[36]  J. Cisneros,et al.  Serology, clinical manifestations and treatment of brucellosis in different age groups , 1990, Infection.

[37]  G. Grollier,et al.  Rifampicin resistance in a strain of Brucella melitensis after treatment with doxycycline and rifampicin. , 1986, The Journal of antimicrobial chemotherapy.

[38]  P. Frenchick,et al.  Inhibition of phagosome-lysosome fusion in macrophages by soluble extracts of virulent Brucella abortus. , 1985, American journal of veterinary research.

[39]  Jay Painter,et al.  Electronic Reprint Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion , 2005 .

[40]  J. Barciszewski,et al.  Methionyl-tRNA synthetase. , 2001, Acta biochimica Polonica.

[41]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[42]  Bernhard Rupp,et al.  Correspondence e-mail: , 2000 .

[43]  M. Al-Sekait.  EPIDEMIOLOGY OF BRUCELLOSIS IN AL MEDINA REGION, SAUDI ARABIA , 2000, Journal of family & community medicine.

[44]  R. Walker.  Standards for antimicrobial susceptibility testing. , 1999, American journal of veterinary research.